Lineage Cell Therapeutics
LCTX
110 hedge funds and large institutions have $112M invested in Lineage Cell Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 39 reducing their positions, and 25 closing their positions.
232% more call options, than puts
Call options by funds: $389K | Put options by funds: $117K
1.18% less ownership
Funds ownership: 44.13% → 42.95% (-1.2%)
11% less funds holding
Funds holding: 124 → 110 (-14)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $182M → $112M (-$69.6M)
49% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 39
52% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$1.44M |
| 2 |
RA
Raffles Associates
New York
|
+$1.18M |
| 3 |
JP Morgan Chase
New York
|
+$879K |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$225K |
| 5 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$155K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.32M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$747K |
| 3 |
Two Sigma Advisers
New York
|
-$736K |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$547K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$499K |
LCTX Hedge Fund Activity: Q1 2022 in Review
110 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2022, worth a combined $112M — down 38% from $182M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of LCTX and 12 opened new positions — a net loss of 13 holders — while 39 trimmed existing stakes and 20 added.
The largest buyer was Broadwood Capital, adding an estimated $1.44M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $1.32M sold.
- 110 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2022, down from 124 in Q4 2021.
- Funds reported $112M of Lineage Cell Therapeutics stock for Q1 2022, down 38% quarter-over-quarter.
- 12 funds opened new Lineage Cell Therapeutics positions in Q1 2022 and 25 closed out, a net change of -13 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2022 was Broadwood Capital, an estimated $1.44M added.
- The largest Lineage Cell Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $1.32M sold.
Based on aggregated 13F filings for Q1 2022.